BioSpace News Archive

 IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with the Division of Infectious Diseases, Department of Medicine at Columbia University, IsoPlexis’ Single-Cell Secretome immune profiling solutions will be used to study cellular drivers of durable and protective immune response to COVID-19.

- Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease (AD) has reached 500 patients toward the study’s previously announced en

JN Nova Pharma Inc. has entered into collaboration with the National Research Council of Canada’s (NRC) Pandemic Response Challenge program to develop a therapeutic pipeline for severe pathologies observed in COVID-19. COVID-19 is not ‘just’ a respiratory infection – it is a complex disease that causes damage to multiple organs, including lung, heart, blood vessels and brain. JN Nova Pharma and the NRC’s team from t

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers (“Evolent”), announced today that it has entered into privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2.00% Convertible Senior Notes due 2021

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised net proceeds of $19.8 million since June 30 ROCHESTER, N.Y., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease and cancer, today announced financial results for

Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“ IONM ”), has appointed Gary Bennett to the newly created position of vice president of revenue. Bennett will be a key member of Assure’s leadership and sales team and will be responsible for planning, scaling, directing and evaluating revenue opportunities. His responsibilities include developing strategies to maxim

Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE! , a lively podcast and interview forum that brings together a broad roster of technology, business and thought leaders from a wide r

Kaskela Law LLC announces that it is investigating Cellular Biomedicine Group, Inc. (“Cellular Biomedicine”) (Nasdaq: CBMG) on behalf of the company’s shareholders. On August 12, 2020 , Cellular Biomedicine announced that it had entered into a definitive agreement whereby each currently outstanding share of the company’s common

Healics is excited to announce it has become a 100% employee-owned ESOP company.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the prospective use of Tempol in a randomized placebo controlled trial.